Skip to main content

Table 1 Baseline characteristics of gastric cancer patients included in this study (N = 86)

From: Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

Characteristics

N (%)

Age at diagnosis, median (min–max) [IQ range]

61 (28–79) [53.6–67.6]

Gender

 Male

44 (51.2)

 Female

42 (48.8)

ECOG PS

 0

45 (52.3)

 1–2

41 (47.7)

Stage

 Locally advanced

36 (41.9)

 Metastatic

50 (58.1)

Previous surgery

 No

33 (38.4)

 Yes

53 (61.6)

Neoadjuvant/adjuvant chemotherapy

 No

61 (70.9)

 Yes

25 (29.1)

Lauren classification

 Intestinal

35 (40.7)

 Diffuse

41 (47.7)

 Mixed

10 (11.6)

Grade

 G2

21 (24.4)

 G3

65 (75.6)

Localization

 Esophagogastric junction

6 (7.0)

 Stomach

80 (93.0)

Agents (N)

 2

36 (41.9)

 3

50 (58.1)

Taxanes (first-line)

 No

39 (45.3)

 Yes

47 (54.7)